Compare COCP & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COCP | ICU |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5M | 15.9M |
| IPO Year | N/A | N/A |
| Metric | COCP | ICU |
|---|---|---|
| Price | $1.11 | $2.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 78.1K | ★ 117.1K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $881,000.00 |
| Revenue This Year | N/A | $691.85 |
| Revenue Next Year | N/A | $64.17 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1195.59 |
| 52 Week Low | $0.90 | $2.20 |
| 52 Week High | $2.67 | $30.70 |
| Indicator | COCP | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 63.13 | 89.96 |
| Support Level | $0.91 | $0.22 |
| Resistance Level | $1.01 | $2.81 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | 0.02 | 0.27 |
| Stochastic Oscillator | 97.62 | 86.88 |
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.